ASPIRA.BO · BSE
Aspira Pathlab & Diagnostics L
₹130
+0.02% (+₹0.03)
Prev. close
₹129.97
Volume
2,616
As of
BSE · may be slightly delayed · 15:32 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aspira Pathlab & Diagnostics L
Aspira Pathlab & Diagnostics Limited owns, manages, runs, and administers various diagnostics centers primarily in India. The company offers biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigation services. It also provides pathology, sonography, x-ray, and radiology tests. The company was formerly known as Utkal Soap Products Limited and changed its name to Aspira Pathlab & Diagnostics Limited in November 2016. Aspira Pathlab & Diagnostics Limited was incorporated in 1973 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Balkrishna Subhash Talawadekar
Headquarters
Mumbai
Employees
168
Website
aspiradiagnostics.comExchange
View on BSE ↗Key stats
Market cap
₹133.78 Cr
P/E ratio (TTM)
1801.0
EPS (TTM)
₹-0.45
Beta (1Y · daily vs NIFTY 50)
-0.06
Beta (5Y · monthly vs NIFTY 50)
-0.41
Shares float
15.73 L
EPS · quarter ended Jun 2026
₹-0.04
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹15.21 Cr | ₹19.54 Cr | ₹14.46 Cr | ₹13.20 Cr | ₹22.00 Cr | ₹24.98 Cr | |
| EBITDA | ₹3.72 Cr | ₹6.47 Cr | ₹1.86 Cr | ₹-81.63 L | ₹3.87 Cr | ₹1.92 Cr |
| ₹1.38 Cr | ₹4.46 Cr | ₹-8.87 L | ₹-2.67 Cr | ₹2.07 Cr | ₹5.13 L | |
| Diluted EPS | — | — | ₹-0.09 | ₹-2.6 | ₹2.01 | ₹0.05 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.34 Cr | ₹14.71 Cr | ₹17.51 Cr | ₹18.51 Cr | |
| — | — | ₹2.35 Cr | ₹1.70 Cr | ₹1.99 Cr | ₹1.97 Cr | |
| Stockholders' equity | — | — | ₹12.75 Cr | ₹10.14 Cr | ₹12.22 Cr | ₹12.23 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-1.20 L | ₹1.05 Cr | ₹1.88 Cr | ₹1.45 Cr | |
| Investing cash flow | — | — | ₹15.93 L | ₹13.78 L | ₹6.58 L | ₹-80.43 L |
| — | — | ₹-93.50 L | ₹-95.41 L | ₹-99.42 L | ₹-1.14 Cr | |
| Capital expenditure | — | — | ₹-13.63 L | ₹-26.32 L | ₹-34.43 L | ₹-69.86 L |
| End cash position | — | — | ₹56.67 L | ₹80.38 L | ₹1.75 Cr | ₹1.26 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Aspira Pathlab & Diagnostics L | ₹137.01 Cr | ₹133.11 | 1801.0 | 11.20 | 0.4% | 0.16 | +13.6% | +117.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 16
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.